Though resistance to “specific precision medicine treatments” of MAPK-mutated HNSCC is yet-to-be unfolded, researchers just begin to report general resistance to Cetuximab, an FDA-approved EGFR targeting antibody for HNSCC, in relation to HRAS mutations. Here, HRAS is linked to head and neck squamous cell carcinoma.